Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics, Biosearch Italia Enter Novel Microbe-Based Drug-Discovery Pact

NEW YORK, Nov. 27 - Myriad Genetics and Biosearch Italia have formed a collaboration to discover novel microbial-based therapeutic compounds, the companies said on Tuesday.

 

Under the terms of the alliance, Biosearch will provide Myriad with access to its library of micro-organisms and microbial extracts, from which Myriad will select promising drug targets and develop high-throughput screening assays.

 

Although financial terms of the deal were not disclosed, the firms said they agreed to share development rights to any resulting compounds. They added that the partnership will not be limited to micro-organism research.

 

"This collaboration will enable Biosearch to recognize value from our natural product library outside our core focus of anti-infectives discovery and development," said Francesco Parenti, president and chief scientific officer of Biosearch Italia.

 

Adrian Hobden, president of Myriad Pharmaceuticals, added: "There is exciting potential through this collaboration.…" Used together, the companies' technologies "may lead to the development of new therapeutics."

 

According to Biosearch, the collaboration "will complement … the extensive drug discovery research conducted directly by Biosearch, making use of its mechanism-based assays."

 

The company, based in Gerenzano, Italy, is known for its rich library of micro-organisms and microbial extracts that it isolates and cultivates in order to obtain a wide range of molecules.

 

Myriad's drug-development approach, meanwhile, relies on its proteomics platform, ProNet, to identify novel drug targets and their disease pathways. The Salt Lake City-based company then screens these targets to identify new lead compounds which it either develops internally or licenses to pharmaceutical companies.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.